Skip to main content
. 2012 Mar 17;27(2):87–96. doi: 10.1016/j.sjopt.2012.03.003

Figure 3.

Figure 3

First order component of MF-ERG among groups. (A) MF-ERG in control group; (B) MF-ERG in diabetic eyes with mild retinopathy in which there is mild reduction of amplitude & delay in latency; (C) MF-ERG in late retinopathy in which no apparent peak and through; and (D) MF-ERG in diabetic subject without retinopathy (just slight delay).